IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
NDA FilingdarovasertibPositive
AI Analysis
Summary
IDEAYA Biosciences announced that its OptimUM-02 Phase 3 trial of darovasertib combination met its primary endpoint in metastatic uveal melanoma. The company is filing an NDA under the real-time oncology review program with expected completion in H2 2026.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
OptimUM-02 trial met primary endpoint; NDA filing underway under real-time oncology review program
Importance:8/10
Sentiment:
0.80
oncologyuveal melanomaPhase 3NDA filingRTORprimary endpoint met
Related Companies
Read the original article
Published by PR Newswire Biotech on August 4, 2026 10:00 AM